Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.
Beconi M, Aziz O, Matthews K, Moumné L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, Bürli RW, McAllister G, Dominguez C, Munoz-Sanjuan I, Beaumont V.
Beconi M, et al. Among authors: woodman b.
PLoS One. 2012;7(9):e44498. doi: 10.1371/journal.pone.0044498. Epub 2012 Sep 4.
PLoS One. 2012.
PMID: 22973455
Free PMC article.